Property developer opposes transfer of loans to NAMA

Lawyers for property developer Paddy McKillen have told the High Court that the aquisition of his loans by NAMA would have significant adverse affects on him, his business and his financial well-being.

Property developer opposes transfer of loans to NAMA
Tue, 05 Oct, 2010 - 14:36

Lawyers for property developer Paddy McKillen have told the High Court that the aquisition of his loans by NAMA would have significant adverse affects on him, his business and his financial well-being.

A challenge by the embattled developer to the transfer of €80m worth of loans from Bank of Ireland to NAMA got underway today.

You have reached your article limit. Already a subscriber? Sign in

Continue reading for €5

Unlock unlimited access and exclusive benefits

CONNECT WITH US TODAY

Whatsapp logo

WHATSAPP

Newsletter logo

NEWSLETTERS

Notification logo

NOTIFICATIONS

Be the first to know the latest news and updates

More in this section

Explosion at Donegal service station Planning granted for new petrol station next to site of Creeslough tragedy
Michael Lyster remembered as ‘magic in human form’ at emotional memorial service Michael Lyster remembered as ‘magic in human form’ at emotional memorial service
AI prompt chat bot. Search website to generate data, text or image. Man using computer with artificial intelligence app. Virtual Mental health experts issue warning over AI 'therapy'
CourtsHeathrowPerson: Paddy McKillenPerson: Attorney General Paul GallagherPerson: McKillenPerson: Senior CounselPerson: Michael CushPerson: CushOrganisation: NAMAOrganisation: High CourtOrganisation: Bank of IrelandOrganisation: European Commission
<p>Sodium valproate, manufactured by Sanofi and sold as Epilim, has been linked to a high risk of serious injury for babies in the womb. File picture</p>

Three more children settle Epilim sodium valproate cases

READ NOW

Lunchtime News

Newsletter

Keep up with stories of the day with our lunchtime news wrap and important breaking news alerts.

Latest

Most Read

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited